STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to…
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development,…
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP)…
HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused…
WARRINGTON, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company…
DEA'S MANDATE IS DRUG DIVERSION, SECURITY AND TO FACILITATE DRUG DEVELOPMENT?DEA DIRECTOR ANNE MILGRAM THINKS DIFFERENTLY. LAW ENFORCEMENT OFFICERS SUFFER.WASHINGTON,…
DUBLIN, IRELAND / ACCESSWIRE / November 8, 2023 / Nemysis is pleased to announce that it has entered into a…
Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S.PALO…
Rolf A. Classon Joins Masimo’s Board of DirectorsIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that Rolf A. Classon has been…
− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 (15 mg and 30…